VIVUS (NASDAQ: VVUS) and ChemoCentryx (NASDAQ:CCXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitabiliy, institutional ownership, risk, valuation, earnings and dividends.

Volatility and Risk

VIVUS has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Institutional & Insider Ownership

35.5% of VIVUS shares are owned by institutional investors. Comparatively, 49.6% of ChemoCentryx shares are owned by institutional investors. 3.0% of VIVUS shares are owned by company insiders. Comparatively, 26.8% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares VIVUS and ChemoCentryx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VIVUS 24.72% 3,747.16% 11.02%
ChemoCentryx N/A -58.48% -21.03%

Analyst Recommendations

This is a summary of current ratings for VIVUS and ChemoCentryx, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VIVUS 0 0 0 0 N/A
ChemoCentryx 0 1 2 0 2.67

ChemoCentryx has a consensus target price of $11.00, suggesting a potential upside of 5.87%. Given ChemoCentryx’s higher probable upside, analysts plainly believe ChemoCentryx is more favorable than VIVUS.

Earnings and Valuation

This table compares VIVUS and ChemoCentryx’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
VIVUS $135.95 million 0.79 $68.49 million $0.33 3.09
ChemoCentryx $20.17 million 24.81 -$31.34 million ($0.65) -15.98

VIVUS has higher revenue and earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than VIVUS, indicating that it is currently the more affordable of the two stocks.

About VIVUS

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

About ChemoCentryx

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.